levofloxacin has been researched along with trimetrexate in 4 studies
Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (trimetrexate) | Trials (trimetrexate) | Recent Studies (post-2010) (trimetrexate) |
---|---|---|---|---|---|
4,346 | 581 | 2,209 | 422 | 50 | 21 |
Protein | Taxonomy | levofloxacin (IC50) | trimetrexate (IC50) |
---|---|---|---|
Dihydrofolate reductase | Mycobacterium avium | 0.3012 | |
Dihydrofolate reductase | Homo sapiens (human) | 0.0207 | |
Dihydrofolate reductase | Lacticaseibacillus casei | 0.1435 | |
Dihydrofolate reductase | Saccharomyces cerevisiae S288C | 0.042 | |
Dihydrofolate reductase | Escherichia coli K-12 | 0.1798 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.026 | |
Dihydrofolate reductase | Pneumocystis carinii | 0.0378 | |
Dihydrofolate reductase | Candida albicans | 0.04 | |
Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.008 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.5788 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.0202 | |
Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0794 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for levofloxacin and trimetrexate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for levofloxacin and trimetrexate
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |